Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FDMT 4D Molecular Therapeutics	$4.34 +1.9%	$3.92	$2.24 ▼ $28.93	$201.05M	2.81	800,466 shs	104,411 shs
KPTI Karyopharm Therapeutics	$4.02 -3.8%	$4.64	$3.51 ▼ $16.95	$34.73M	0.24	85,380 shs	68,392 shs
OGI Organigram Global	$1.47 +0.4%	$1.36	$0.85 ▼ $2.08	$197.56M	1.36	663,771 shs	278,627 shs
PRME Prime Medicine	$3.86 -4.5%	$2.13	$1.11 ▼ $6.62	$519.82M	2.33	1.76 million shs	3.89 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FDMT 4D Molecular Therapeutics	+2.40%	-3.62%	-2.52%	+39.22%	-84.07%
KPTI Karyopharm Therapeutics	-1.42%	-13.10%	-7.93%	-15.56%	-72.13%
OGI Organigram Global	+2.10%	+1.39%	+2.10%	+36.45%	-16.57%
PRME Prime Medicine	-5.83%	-11.01%	+169.33%	+225.81%	-39.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FDMT 4D Molecular Therapeutics	2.3805 of 5 stars	3.3	3.0	0.0	1.9	1.7	0.6
KPTI Karyopharm Therapeutics	3.8149 of 5 stars	3.4	0.0	4.6	2.2	2.5	0.6
OGI Organigram Global	1.1303 of 5 stars	0.0	1.0	0.0	3.1	0.0	2.5
PRME Prime Medicine	3.8288 of 5 stars	4.4	1.0	0.0	3.0	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	581.00% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$37.40	830.35% Upside
OGI Organigram Global	0.00	N/A	N/A	N/A
PRME Prime Medicine	2.75	Moderate Buy	$9.25	139.70% Upside

Current Analyst Ratings Breakdown

Latest KPTI, FDMT, OGI, and PRME Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/20/2025	PRME Prime Medicine	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $6.00
5/20/2025	PRME Prime Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FDMT 4D Molecular Therapeutics	$23K	8,741.33	N/A	N/A	$11.05 per share	0.39
KPTI Karyopharm Therapeutics	$145.24M	0.24	N/A	N/A	($22.10) per share	-0.18
OGI Organigram Global	$117.47M	1.67	N/A	N/A	$2.07 per share	0.71
PRME Prime Medicine	$3.85M	134.95	N/A	N/A	$1.37 per share	2.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/6/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)
OGI Organigram Global	-$33.39M	$0.10	14.75	N/A	N/A	8.05%	-5.93%	-4.39%	8/12/2025 (Estimated)
PRME Prime Medicine	-$198.13M	-$1.61	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A

Latest KPTI, FDMT, OGI, and PRME Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.6922	N/A	N/A	N/A	$0.52 million	N/A
8/12/2025	Q3 2025	OGI Organigram Global	-$0.01	N/A	N/A	N/A	$68.04 million	N/A
8/5/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.72	N/A	N/A	N/A	$37.92 million	N/A
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	37.47%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
OGI Organigram Global	N/A	3.42	1.90
PRME Prime Medicine	N/A	6.50	6.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FDMT 4D Molecular Therapeutics	99.27%
KPTI Karyopharm Therapeutics	66.44%
OGI Organigram Global	34.63%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
FDMT 4D Molecular Therapeutics	9.60%
KPTI Karyopharm Therapeutics	2.98%
OGI Organigram Global	0.09%
PRME Prime Medicine	22.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.38 million	Optionable
OGI Organigram Global	860	133.94 million	133.82 million	Optionable
PRME Prime Medicine	234	134.49 million	100.38 million	Optionable

KPTI, FDMT, OGI, and PRME Headlines

Recent News About These Companies

Prime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic Advancements

July 17 at 7:52 AM | tipranks.com

Prime Medicine Shares Drop After New Funding, Equity Investment

July 16 at 5:40 PM | marketwatch.com

Prime Medicine (NYSE:PRME) Sees Large Volume Increase - Here's Why

July 16 at 1:00 PM | marketbeat.com

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

July 16 at 8:10 AM | businesswire.com

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

July 16 at 7:00 AM | globenewswire.com

Prime Medicine (NYSE:PRME) Trading 7.4% Higher - Should You Buy?

July 14 at 12:29 PM | marketbeat.com

Prime Medicine (NYSE:PRME) Shares Down 11.8% - Should You Sell?

July 11, 2025 | marketbeat.com

Prime Medicine (NYSE:PRME) Sees Strong Trading Volume - What's Next?

July 9, 2025 | marketbeat.com

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

July 7, 2025 | seekingalpha.com

Prime Medicine stock soars amid gene editing sector momentum

July 7, 2025 | finance.yahoo.com

Prime Medicine, Inc.: Buy Rating Driven by Strategic Positioning and Market Momentum

July 7, 2025 | tipranks.com

Stock Traders Purchase High Volume of Prime Medicine Call Options (NYSE:PRME)

July 7, 2025 | marketbeat.com

Prime Medicine (NYSE:PRME) Shares Gap Up - What's Next?

July 7, 2025 | marketbeat.com

Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data

July 6, 2025 | msn.com

Sumitomo Mitsui Trust Group Inc. Sells 164,157 Shares of Prime Medicine, Inc. (NYSE:PRME)

July 4, 2025 | marketbeat.com

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by Analysts

June 29, 2025 | marketbeat.com

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder David R. Liu Purchases 21,000 Shares

June 24, 2025 | insidertrades.com

Insider Buying: Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Purchases 21,000 Shares of Stock

June 23, 2025 | marketbeat.com

Prime Medicine’s Technological Edge and Strategic Positioning Highlighted as Key Investment Opportunity

June 17, 2025 | tipranks.com

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $31,290.00 in Stock

June 17, 2025 | insidertrades.com

Prime Medicine to Participate in Upcoming Investor Conferences

May 29, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Hot Tech Stocks Showing Bullish Price Action Right Now
By Thomas Hughes | July 11, 2025
View 3 Hot Tech Stocks Showing Bullish Price Action Right Now
Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
By Leo Miller | June 25, 2025
View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
Geospace Stock Skyrockets After Major Petrobras Contract
By Jeffrey Neal Johnson | June 24, 2025
View Geospace Stock Skyrockets After Major Petrobras Contract
Why Occidental's Price Dip Signals a Buying Opportunity
By Jeffrey Neal Johnson | July 3, 2025
View Why Occidental's Price Dip Signals a Buying Opportunity

KPTI, FDMT, OGI, and PRME Company Descriptions

4D Molecular Therapeutics NASDAQ:FDMT

$4.34 +0.08 (+1.88%)

As of 01:21 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Karyopharm Therapeutics NASDAQ:KPTI

$4.02 -0.16 (-3.83%)

As of 01:21 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Organigram Global NASDAQ:OGI

$1.47 +0.01 (+0.41%)

As of 01:21 PM Eastern

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

Prime Medicine NYSE:PRME

$3.86 -0.18 (-4.48%)

As of 01:21 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time